SDGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Schrodinger Inc (SDGR) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company has shown some positive developments in its software and drug discovery segments, the financial performance, technical indicators, and analyst ratings suggest a cautious approach. The stock lacks strong immediate catalysts, and the technical trend is bearish. It would be prudent to wait for clearer signs of upward momentum or stronger financial performance before investing.
The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. The stock is trading near its pivot point of 12.045, with resistance at 12.905 and support at 11.185.
Q4 2025 earnings showed a 23% increase in total revenue.
Drug discovery revenue more than doubled, and the company is transitioning to a hosted licensing model with expected growth in annual contract value.
Operating expenses decreased by 9%, indicating cost management improvements.
Financial performance in Q4 2025 showed a significant decline in net income (-180.84% YoY) and EPS (-180.00% YoY).
Gross margin dropped by 9.54% YoY.
Analysts have lowered price targets recently, reflecting concerns about competition and regulatory impacts.
In Q4 2025, revenue decreased slightly by -1.23% YoY to $87.2 million. Net income and EPS saw significant declines of -180.84% and -180.00% YoY, respectively. Gross margin dropped to 65.68%, down 9.54% YoY. Despite revenue growth in specific segments, overall financial performance was weak.
Analysts have mixed views. Morgan Stanley maintains an Equal Weight rating with a price target of $19. KeyBanc and TD Cowen lowered their price targets but maintain Overweight and Buy ratings, respectively. UBS initiated coverage with a Neutral rating and an $18 price target. Recent downgrades in price targets reflect cautious optimism but highlight concerns about competition and valuation.
